Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis.
about
High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literatureTissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.The endocannabinoid system links gut microbiota to adipogenesisGenetically modified flax expressing NAP-SsGT1 transgene: examination of anti-inflammatory action.Endocannabinoids in liver disease.Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosisAn amphipathic alpha-helical peptide from apolipoprotein A1 stabilizes protein polymer vesicles.The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsMelanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.A multi-mineral natural product inhibits liver tumor formation in C57BL/6 mice.Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.Intestinal GATA4 deficiency protects from diet-induced hepatic steatosisLiver X receptor α is essential for the capillarization of liver sinusoidal endothelial cells in liver injuryHedgehog signalling regulates liver sinusoidal endothelial cell capillarisationRole of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in ratsDysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteinsHybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosisHDL as a biomarker, potential therapeutic target, and therapyStructure and function of HDL mimetics.Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.Liver sinusoidal endothelial cells in hepatic fibrosisThe dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression.Proteomic Analysis Reveals Dab2 Mediated Receptor Endocytosis Promotes Liver Sinusoidal Endothelial Cell Dedifferentiation.Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin.The Injury-Related Activation of Hedgehog Signaling Pathway Modulates the Repair-Associated Inflammation in Liver Fibrosis.Liver Sinusoidal Endothelial Cell: An Update.A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies.Role of canonical Hedgehog signaling pathway in liver
P2860
Q26996600-40D9CF67-3DB3-4A9A-A77A-40ACBF30D194Q33556288-9ECE387D-E1AC-457D-9310-878149F51E43Q33714587-388AE38B-447F-4CAB-B9B5-77609613D7AAQ34078880-64392841-AC11-4E62-AF72-7E6552219CB4Q34358991-7A8010A8-A8CD-4BD3-A441-C49FA55178C6Q34776919-CDC79CA4-E128-45A4-B7C6-143C32423612Q35056710-EF2714DF-75FF-43DC-8613-09C1087D05E8Q35082742-1A9D2144-C59B-4112-B53B-1DAEFC8F0501Q35193292-E5EF43FA-C34F-432E-A6FB-07254C0DBAE4Q35474335-EEF11271-386A-48AF-BAEF-EE7804059C95Q35562084-2193BDD7-2950-4EC7-9C72-3FD4CAF8271EQ35990259-EA6CC25B-EA8F-4262-AE31-660BEAD069E4Q36295444-7FEE90F1-9655-440F-A5F3-484C7B3F9FA2Q36336508-87D4C7D1-D31F-4304-A7E3-443292ABECF1Q36591996-981EA2F3-1EB1-45A0-AC37-572C1013570AQ36677171-CAF7187F-C66B-4319-9879-13619918E3CCQ36746393-81AEE88C-2053-4306-BA54-141E71020497Q36763561-A6092358-E389-45B5-B5B8-97D3BDF68248Q37164508-602A743C-91FC-44FB-AFDA-35DBFF1DC25BQ37429173-52CFA5CC-4A0D-402E-AB4C-FD435D727DE0Q37553765-5B7CB98F-7970-4CC3-88C6-74EA51644BB3Q37581457-C8DF4FE4-8D86-4D03-A606-5E792C7E03E3Q38240680-56812356-8B08-4F2A-89EE-2AF86A54087EQ38527356-32C24738-8F30-4ED5-84C6-1294ED107F1CQ39031169-576360EE-4D7B-4135-B195-1A6E875007BCQ42677444-85649E5E-1F25-48EC-96F2-1DBA6A878F1CQ46503559-47EF99E7-F175-4366-BB76-B7E9057062BAQ47126762-CBD67373-ECF9-48A0-995C-8F7C939638A7Q49612880-15371C0C-6E88-473D-8F4A-488EF44CF6FDQ50526595-BF53C012-74CE-433B-9C6D-F5C027EC7F40Q58758006-D4690554-60DB-496A-8B8A-FB8388F92B80
P2860
Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Prevention of hepatic fibrosis ...... nonalcoholic steatohepatitis.
@en
type
label
Prevention of hepatic fibrosis ...... nonalcoholic steatohepatitis.
@en
prefLabel
Prevention of hepatic fibrosis ...... nonalcoholic steatohepatitis.
@en
P2093
P2860
P1476
Prevention of hepatic fibrosis ...... nonalcoholic steatohepatitis.
@en
P2093
Gary C Kanel
Laurie D DeLeve
Robert S McCuskey
Roscoe D Atkinson
Xiangdong Wang
P2860
P304
P356
10.2353/AJPATH.2008.070720
P407
P577
2008-09-04T00:00:00Z